RxDoctor Payments DataLook up a doctor →

Amber Shull, PA

Medical · Norton Shores, MINPI 1770546749

Payments from drug & device makers

$153,913in general payments, 2019–2025

Across 1,189 payments — averaging $129.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$60K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40K
  • Teva Pharmaceuticals USA, Inc.$28K
  • Otsuka America Pharmaceutical, Inc.$17K
  • Supernus Pharmaceuticals, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $6K from 45 others

What the payments were for

  • Consulting fees$5,9354%
  • Speaking & faculty fees$120,63778%
  • Travel & lodging$10,2577%
  • Food & beverage$17,03011%
  • Education$540%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,913 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$7,853
Medicare patients
16
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine21$162,092
VraylarCariprazine Hcl107$145,155
RexultiBrexpiprazole67$95,601
CaplytaLumateperone Tosylate38$62,267
TrintellixVortioxetine Hydrobromide32$16,610
AuvelityDextromethorphan Hbr/Bupropion14$14,684
Desvenlafaxine Succinate ErDesvenlafaxine Succinate271$11,420
Fluvoxamine Maleate ErFluvoxamine Maleate12$5,794
Mirtazapine75$2,019
Paliperidone ErPaliperidone19$1,831
Vilazodone Hcl18$1,670
Lamotrigine ErLamotrigine21$1,654
Buspirone Hcl142$1,535
Quetiapine Fumarate ErQuetiapine Fumarate69$1,528
Ziprasidone Hcl24$1,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$28,176$162,09221 claims
AbbVieVraylar$60,209$145,155107 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17,026$95,60167 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$39,728$62,26738 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$358$16,61032 claims
Axsome Therapeutics, Inc.Auvelity$463$14,68414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.

Other medical in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →